Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Marizomib (ML858) is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM, respectively.
パッケージサイズ | 在庫状況 | 単価(税別) | |
---|---|---|---|
1 mg | 在庫あり | ¥ 158,500 | |
5 mg | 在庫あり | ¥ 335,000 | |
10 mg | 在庫あり | ¥ 452,500 | |
25 mg | 在庫あり | お問い合わせ | |
50 mg | 約10-14 週間 | お問い合わせ |
説明 | Marizomib (ML858) is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM, respectively. |
ターゲット&IC50 | CTL laspase-like:28 nM, CTL:3.5 nM, Trypsin like:430 nM |
別名 | NPI-0052, Salinosporamide A, ML858 |
分子量 | 313.78 |
分子式 | C15H20ClNO4 |
CAS No. | 437742-34-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31.38 mg/mL (100 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Marizomib 437742-34-2 Proteases/Proteasome Ubiquitination Proteasome NPI-0052 Salinosporamide A NPI 0052 ML858 ML-858 NPI0052 ML 858 Inhibitor inhibitor inhibit